[{"id":"b9a406bd-d975-4b31-a433-86da8522fc92","acronym":"TAS-120-202","url":"https://clinicaltrials.gov/study/NCT04189445","created_at":"2021-01-19T19:00:59.221Z","updated_at":"2025-02-25T16:44:46.191Z","phase":"Phase 2","brief_title":"Futibatinib in Patients With Specific FGFR Aberrations","source_id_and_acronym":"NCT04189445 - TAS-120-202","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 amplification • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 amplification • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 11/11/2024","primary_completion_date":" 11/11/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-05"},{"id":"0147b8e4-e331-432b-853a-2dc46c0ae9a0","acronym":"FIGHT-203","url":"https://clinicaltrials.gov/study/NCT03011372","created_at":"2021-01-18T14:48:52.779Z","updated_at":"2024-07-02T16:35:04.338Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)","source_id_and_acronym":"NCT03011372 - FIGHT-203","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-10"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"34bea2f2-8a1e-4060-9d83-36b2c4268cbc","acronym":"Study 0314","url":"https://clinicaltrials.gov/study/NCT02268253","created_at":"2021-01-18T10:39:50.644Z","updated_at":"2024-07-02T16:35:52.835Z","phase":"Phase 2","brief_title":"Tagraxofusp (SL-401) in Patients With CMML or MF","source_id_and_acronym":"NCT02268253 - Study 0314","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" PDGFRA • JAK2 • PDGFRB • PCM1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["PDGFRA • JAK2 • PDGFRB • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 03/07/2023","study_completion_date":" 03/07/2023","last_update_posted":"2023-03-21"},{"id":"fda6b348-a56b-40aa-9321-d8dc4bbbe723","acronym":"","url":"https://clinicaltrials.gov/study/NCT05521204","created_at":"2022-08-30T20:55:57.190Z","updated_at":"2024-07-02T16:36:04.755Z","phase":"Phase 2","brief_title":"Olverembatinib for FGFR1-rearranged Neoplasms","source_id_and_acronym":"NCT05521204","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2027","study_completion_date":" 08/31/2027","last_update_posted":"2022-08-30"}]